shares of atai life sciences nv atai tumbled about 44 in premarket trading on friday after the company said a phase 2a clinical trial evaluating a ketamine therapy for treatmentresistant depression did not meet the primary endpoint atai’s stock has declined 601 over the past year while the sp 500 spx is down 190